Latest Breaking News On - Jacques bouchy - Page 2 : comparemela.com

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Jacques bouchyThierry guillaudeuxJohn mullalySociety for immunotherapy of cancerLifesci advisorsKineta incSan diego convention centerInvestor relations business developmentPresents new preclinical dataAntibody showed high binding affinityStrongt cell activationVivo antitumor efficacySingle agentCheckpoint inhibitorsHematological tumorChief scientific officer

Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023

Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSan diego convention centerJohn mullalyThierry guillaudeuxJacques bouchyKineta incLifesci advisorsInvestor relations business developmentSociety for immunotherapy of cancerAntibody abstracts acceptedPoster presentationsAnnual meetingChief scientific officerExhibit hallsDiego convention

Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023

SEATTLE, Oct. 09, 2023 Kineta, Inc. , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced.

San diegoUnited statesThierry guillaudeuxJacques bouchyJohn mullalyGlobenewswire incMonoclonal antibody programInvestor relations business developmentDiscovery developmentKineta incLifesci advisorsOxford global immunoChief scientific officerCell therapiesBusiness developmentSci advisors

Kineta to Present Preclinical Data on VISTA Blocking

SEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel.

San diegoUnited statesThierry guillaudeuxJacques bouchyJohn mullalyLifesci advisorsMonoclonal antibody programInvestor relations business developmentKineta incDiscovery developmentOxford global immunoChief scientific officerCell therapiesConference roomBusiness developmentSci advisors

Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023

Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesJacques bouchyJohn mullalyThierry guillaudeuxDiscovery developmentMonoclonal antibody programInvestor relations business developmentKineta incLifesci advisorsOxford global immunoChief scientific officerCell therapiesConference roomBusiness developmentSci advisors